Joshua J. Mcfarlane

Hematology | Hematology Oncology

8007 Discovery Drive
Suite A
Richmond, VA 23229

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4 publications

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Journal: Clinical genitourinary cancer

Published: January 17, 2020

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.

Journal: Clinical genitourinary cancer

Published: January 17, 2020

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

Journal: The oncologist

Published: February 18, 2017

Secondary colorectal carcinoma after childhood cancer.

Secondary colorectal carcinoma after childhood cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 06, 2012

Showing 1-4 of 4

Last Updated: 09/26/2026